Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) saw a significant drop in short interest in September. As of September 30th, there was short interest totalling 14,180,000 shares, a drop of 5.7% from the September 15th total of 15,040,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is currently 8.8 days.
Wall Street Analyst Weigh In
A number of analysts have weighed in on FATE shares. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a research note on Wednesday, August 14th. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a report on Thursday, August 22nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.90.
View Our Latest Stock Report on Fate Therapeutics
Fate Therapeutics Trading Up 5.2 %
Fate Therapeutics (NASDAQ:FATE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.14. Fate Therapeutics had a negative return on equity of 44.09% and a negative net margin of 1,426.67%. The company had revenue of $6.77 million for the quarter, compared to analyst estimates of $1.47 million. On average, sell-side analysts predict that Fate Therapeutics will post -1.73 EPS for the current year.
Institutional Investors Weigh In On Fate Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of FATE. Ausdal Financial Partners Inc. acquired a new stake in shares of Fate Therapeutics during the 2nd quarter valued at approximately $33,000. Dark Forest Capital Management LP acquired a new stake in shares of Fate Therapeutics during the 2nd quarter valued at approximately $63,000. DRW Securities LLC acquired a new stake in shares of Fate Therapeutics during the 2nd quarter valued at approximately $71,000. Arizona State Retirement System acquired a new stake in shares of Fate Therapeutics during the 2nd quarter valued at approximately $84,000. Finally, Headlands Technologies LLC lifted its position in shares of Fate Therapeutics by 5,258.6% during the 2nd quarter. Headlands Technologies LLC now owns 28,508 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 27,976 shares during the period. 97.54% of the stock is currently owned by institutional investors and hedge funds.
About Fate Therapeutics
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Articles
- Five stocks we like better than Fate Therapeutics
- Stock Sentiment Analysis: How it Works
- Should Warren Buffett’s Favorite Stock be Yours Too?
- What is Put Option Volume?
- Why Buffett Loves Occidental Stock And What It Means for Chevron
- Financial Services Stocks Investing
- UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.